MAGEA3 and neoplasm: Finally, another study demonstrated that the MAGE-A3 antigen, frequently expressed in MCC, was recognized by CD8 TILs obtained from a virus-negative MCC tumor, suggesting that MAGE-A3 could potentially serve as a target for immunotherapy in virus-negative MCC case [20].